Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Opicapone

FDA-approved product (capsule, oral), marketed as Ongentys.

Registered studies
49
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Opicapone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Parkinson disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other dopaminergic agents
FDA pharmacologic class
Catechol-O-Methyltransferase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Opicapone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Opicapone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Opicapone in Clinical Practice

    NCT02847442 · start 2016-11-23

    Registered record
    Registry ID
    NCT02847442
    Conditions
    Parkinson's Disease With Wearing-off Motor Fluctuations
    Interventions
    BIA 9-1067; levodopa/dopa decarboxylase inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-11-23
    Completion
    2018-07-04
    Enrolment
    518

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease With Wearing-off Motor Fluctuations
    InterventionBIA 9-1067; levodopa/dopa decarboxylase inhibitor
    PhasePhase 4
    Registry statusCompleted

  • Effect of Food on Opicapone

    NCT03116308 · start 2014-11-21

    Registered record
    Registry ID
    NCT03116308
    Conditions
    Parkinson Disease
    Interventions
    Opicapone (OPC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-11-21
    Completion
    2015-01-28
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOpicapone (OPC)
    PhasePhase 1
    Registry statusCompleted

  • Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers

    NCT02305017 · start 2014-03

    Registered record
    Registry ID
    NCT02305017
    Conditions
    Parkinson's Disease
    Interventions
    BIA 9-1067; Paracetamol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03
    Completion
    2014-04
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionBIA 9-1067; Paracetamol
    PhasePhase 1
    Registry statusCompleted

  • Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

    NCT02305030 · start 2014-03

    Registered record
    Registry ID
    NCT02305030
    Conditions
    Parkinson's Disease
    Interventions
    BIA 9-1067; Warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03
    Completion
    2014-05
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionBIA 9-1067; Warfarin
    PhasePhase 1
    Registry statusCompleted

  • Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers

    NCT02305277 · start 2014-03

    Registered record
    Registry ID
    NCT02305277
    Conditions
    Parkinson
    Interventions
    BIA 9-1067 (clinical micronized, CM); BIA 9-1067 (to-be-marketed, TBM)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03
    Completion
    2014-06
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson
    InterventionBIA 9-1067 (clinical micronized, CM); BIA 9-1067 (to-be-marketed, TBM)
    PhasePhase 1
    Registry statusCompleted

  • Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

    NCT02305316 · start 2014-02

    Registered record
    Registry ID
    NCT02305316
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067 non-micronized; BIA 9-1067 micronized
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02
    Completion
    2014-03
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067 non-micronized; BIA 9-1067 micronized
    PhasePhase 1
    Registry statusCompleted

  • Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

    NCT02305329 · start 2014-02

    Registered record
    Registry ID
    NCT02305329
    Conditions
    Epilepsy
    Interventions
    BIA 9-1067
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02
    Completion
    2014-04
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionBIA 9-1067
    PhasePhase 1
    Registry statusCompleted

  • Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

    NCT01851850 · start 2013-05

    Registered record
    Registry ID
    NCT01851850
    Conditions
    Parkinson Disease
    Interventions
    Opicapone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-05
    Completion
    2016-05-24
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOpicapone
    PhasePhase 3
    Registry statusCompleted

  • The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

    NCT02170376 · start 2011-09

    Registered record
    Registry ID
    NCT02170376
    Conditions
    Parkinson's Disease (PD)
    Interventions
    BIA 9-1067; Entacapone; Placebo; Levodopa/carbidopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09
    Completion
    2012-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD)
    InterventionBIA 9-1067; Entacapone; Placebo; Levodopa/carbidopa
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

    NCT01520987 · start 2011-05

    Registered record
    Registry ID
    NCT01520987
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-11
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

    NCT01227655 · start 2011-03

    Registered record
    Registry ID
    NCT01227655
    Conditions
    Parkinson's Disease
    Interventions
    BIA 9-1067; Placebo; Levodopa; Carbidopa; Benserazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-07
    Enrolment
    427

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionBIA 9-1067; Placebo; Levodopa; Carbidopa +1 more
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

    NCT01568073 · start 2011-03

    Registered record
    Registry ID
    NCT01568073
    Conditions
    Parkinson's Disease
    Interventions
    BIA 9-1067; Entacapone; Placebo; Levodopa; Carbidopa; Benserazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03
    Completion
    2013-11
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionBIA 9-1067; Entacapone; Placebo; Levodopa +2 more
    PhasePhase 3
    Registry statusCompleted

  • An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

    NCT02169427 · start 2011-03

    Registered record
    Registry ID
    NCT02169427
    Conditions
    Parkinson's Disease (PD)
    Interventions
    OPC
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-03
    Completion
    2011-07
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD)
    InterventionOPC
    PhasePhase 1
    Registry statusCompleted

  • Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

    NCT01532115 · start 2010-05

    Registered record
    Registry ID
    NCT01532115
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067; Placebo; moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-05
    Completion
    2011-05
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067; Placebo; moxifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

    NCT02101190 · start 2010-03

    Registered record
    Registry ID
    NCT02101190
    Conditions
    Parkinson's Disease
    Interventions
    BIA 9-1067
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2010-05
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionBIA 9-1067
    PhasePhase 1
    Registry statusCompleted